Impact of Low-Dose Melatonin Supplementation on Testosterone Levels in U.S. Adult Males



      Amidst the rapid rise in melatonin supplementation, decreased testosterone levels amongst males in recent decades, and the unclear association between melatonin and the hypogonadal-pituitary-gland (HPG) axis, this study aimed to further examine the association between melatonin use and testosterone levels among men in a nationally representative sample.


      U.S. men over the age of 18 surveyed from 2011-2016 via the National Health and Nutrition Examination Survey (NHANES) without missing demographic or pertinent health information were included in the analysis. A total testosterone (TT) level of less than 300 ng/dL was considered low. An average daily dose (ADD) was calculated to quantify participants’ exposure to melatonin supplementation in the past 30 days.


      Analysis included 7,656 participants after selection criteria. The median age of participants was 47 [31-63] years old; the median TT level was 389.9 [289 - 513.9] ng/dL. Melatonin intake was reported in 51 (0.7%) individuals with an ADD of 1 [0.4 - 3] mg/day. We found no association between melatonin intake in the past 30 days and low TT levels (OR = 0.958, 95% CI: 0.496 -1.850; P=0.898). As expected, increasing BMI (OR = 1.133, 95% CI: 1.122 – 1.144; P < 0.001) and older age (OR = 1.019, 95% CI: 1.016 – 1.022; P < 0.001) were associated with low TT levels.


      Predominantly low-dose melatonin supplementation was not associated with low TT levels. Future studies are needed to better quantify the relationship between melatonin intake and low TT levels, especially in the setting of supratherapeutic doses and prolonged periods of exposure.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Li J
        • Somers VK
        • Xu H
        • Lopez-Jimenez F
        • Covassin N.
        Trends in use of melatonin supplements among US adults, 1999-2018.
        JAMA. 2022; 327: 483-485
        • Akhtar A.
        Americans Have Turned to Melatonin to Soothe Pandemic-Induced Stress. Experts Worry High Demand, Little Federal Oversight, and Insufficient Data Leave the Industry Ripe for Scams. Insider. Business Insider Inc., 2021
        • Boafo A
        • Greenham S
        • Alenezi S
        • et al.
        Could long-term administration of melatonin to prepubertal children affect timing of puberty? A clinician's perspective.
        Nat Sci Sleep. 2019; 11: 1-10
        • Webley GE
        • Böhle A
        • Leidenberger FA.
        Positive relationship between the nocturnal concentrations of melatonin and prolactin, and a stimulation of prolactin after melatonin administration in young men.
        J Pineal Res. 1988; 5: 19-33
        • Li C
        • Zhou X.
        Melatonin and male reproduction.
        Clin Chim Acta. 2015; 446: 175-180
        • Yang M
        • Guan S
        • Tao J
        • et al.
        Melatonin promotes male reproductive performance and increases testosterone synthesis in mammalian Leydig cells†.
        Biol Reprod. 2021; 104: 1322-1336
        • Qin F
        • Zhang J
        • Zan L
        • et al.
        Inhibitory effect of melatonin on testosterone synthesis is mediated via GATA-4/SF-1 transcription factors.
        Reprod Biomed Online. 2015; 31: 638-646
        • Patel P
        • Shiff B
        • Kohn TP
        • Ramasamy R.
        Impaired sleep is associated with low testosterone in US adult males: results from the National Health and Nutrition Examination Survey.
        World J Urol. 2019; 37: 1449-1453
        • Ahluwalia N
        • Dwyer J
        • Terry A
        • Moshfegh A
        • Johnson C.
        Update on NHANES dietary data: focus on Collection, release, analytical considerations, and uses to inform public policy.
        Adv Nutr. 2016; 7: 121-134
        • Mulhall JP
        • Trost LW
        • Brannigan RE
        • et al.
        • AUA Guideline:
        Evaluation and management of testosterone deficiency: AUA guideline.
        J Urol. 2018; 200: 423
        • Lokeshwar SD
        • Patel P
        • Fantus RJ
        • et al.
        Decline in Serum Testosterone Levels Among Adolescent and Young Adult Men in the USA.
        Eur Urol Focus. 2021; 7: 886-889
        • Shi L
        • Li N
        • Bo L
        • Xu Z.
        Melatonin and hypothalamic-pituitary-gonadal axis.
        Curr Med Chem. 2013; 20: 2017-2031
        • Zhang Y
        • Cong P
        • Tong C
        • Jin H
        • Liu Y
        • Hou M.
        Melatonin pretreatment alleviates blast-induced oxidative stress in the hypothalamic-pituitary-gonadal axis by activating the Nrf2/HO-1 signaling pathway.
        Life Sci. 2021; 280119722
        • Kelestimur H
        • Ozcan M
        • Kacar E
        • Alcin E
        • Yılmaz B
        • Ayar A.
        Melatonin elicits protein kinase C-mediated calcium response in immortalized GT1-7 GnRH neurons.
        Brain Res. 2012; 1435: 24-28
        • Kovac JR
        • Pan M
        • Arent S
        • Lipshultz LI.
        Dietary adjuncts for improving testosterone levels in hypogonadal males.
        Am J Mens Health. 2016; 10: NP109-NP117
        • Schlegel PN.
        Aromatase inhibitors for male infertility.
        Fertil Steril. 2012; 98: 1359-1362
        • Wheeler KM
        • Sharma D
        • Kavoussi PK
        • Smith RP
        • Costabile R.
        Clomiphene citrate for the treatment of hypogonadism.
        Sex Med Rev. 2019; 7: 272-276